MANAR ABDALLA: Open Payments
NPI 1700632411 · CHICAGO, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,445 in 61 payments from 26 companies in 2025. Trend: 2023 $0 · 2024 $1,139 · 2025 $1,445
Food & beverage: $1,445
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 8 | $185 |
| Ardelyx, Inc. | 5 | $147 |
| Alpha Cognition USA, Inc. | 2 | $107 |
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $101 |
| Kowa Pharmaceuticals America, Inc. | 5 | $99 |
| AstraZeneca Pharmaceuticals LP | 4 | $90 |
| SCILEX PHARMACEUTICALS INC. | 3 | $64 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $63 |
| ABBVIE INC. | 2 | $59 |
| GlaxoSmithKline, LLC. | 2 | $51 |
Products named: IBSRELA, Ozempic, Zunveyl, Kerendia, ZORYVE, ZTLido, CAPLYTA, REXULTI.
Industry payments across IL — which companies pay providers there.
